IBA Dosimetry expands its myQA® iON technology into Radiation Therapy

IBA continues to shape the future of QA with expansion of technology into additional treatment indications

Louvain-La-Neuve, Belgium, 24 October, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of dosimetry solutions, is pleased to announce the expansion of its myQA® iON into Radiation Therapy at the ASTRO 2022 Annual Meeting.

Building upon on the success of the myQA® iON for Proton Therapy, IBA Dosimetry has expanded the use of the technology into linac-based Radiation Therapy. myQA® iON significantly increases the efficiency and accuracy of patient quality assurance (QA) procedures by combining log file analysis, best-in-class Monte Carlo calculation, and workflow automation into one software solution. IBA is working on implementing 2D and 3D measurements in the future.

These powerful features deliver high sensitivity for error detection and clinical ease of use. myQA® iON maximizes the certainty of QA results while significantly reducing the time required for patient QA.

“The expansion of our myQA® iON solution into Radiation Therapy further advances patient quality assurance in this therapeutic area. It enables customers to validate their most demanding treatment techniques while ensuring patient safety without compromise,” said Jean-Marc Bothy, President of IBA Dosimetry.

Lourens Strauss, Medical Physicist at the University of the Free State, Bloemfontein, South Africa, said: “The automation of the workflow speeds up patient QA considerably, yet still provides comprehensive analysis and supreme Monte Carlo dose accuracy. The myQA® iON software allows for full automation, but I have the freedom to maintain control of the functionality.” 

Ralf Dreindl, Medical Physicist at MedAustron Iontherapy Center, Austria commented: “We have seen immediate efficiency gains since our team implemented clinically myQA® iON for Proton Therapy in 2019. During the first two months of operation, we noted an average 24% reduction in patient-specific QA measurements. Multiple-field optimized beams are also now part of the mix for independent dose check, yielding up to a 50% reduction in patient-specific QA measurements.”




About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the areas of industrial sterilization, radiopharmaceuticals, and dosimetry. Based in Louvain-la-Neuve, Belgium, the company employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest verified social and environmental performance standards.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com



Christine Zollbrecht
IBA Dosimetry Marketing Director

+32 10 475 890

Olivier Lechien
Corporate Communication Director
+32 10 475 890

Consilium Strategic Communications
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700